Cargando…

Casirivimab-Imdevimab (REGN-COV2) for Mild to Moderate SARS-CoV-2 Infection in Kidney Transplant Recipients

Detalles Bibliográficos
Autores principales:	Liu, Esther C., Lee, Jennifer H., Loo, Angela, Mazur, Shawn, Sultan, Sam, Aull, Meredith, Lee, Jun B., Muthukumar, Thangamani, Hartono, Choli
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2021
Materias:	Research Letter
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8418987/ https://www.ncbi.nlm.nih.gov/pubmed/34514186 http://dx.doi.org/10.1016/j.ekir.2021.08.032

Ejemplares similares

Persistent SARS-CoV-2 infection in patients with secondary antibody deficiency: successful clearance following combination casirivimab and imdevimab (REGN-COV2) monoclonal antibody therapy
por: Taha, Yusri, et al.
Publicado: (2021)

Casirivimab/Imdevimab: First Approval
por: Deeks, Emma D.
Publicado: (2021)

Casirivimab and imdevimab for COVID-19
Publicado: (2022)

Casirivimab/imdevimab: Various toxicities: 2 case reports
Publicado: (2022)

Multisystem Inflammatory Syndrome in an Adult Who Received Casirivimab-Imdevimab (REGEN-COV)
por: Singh, Gurdeep, et al.
Publicado: (2022)

A SEVERE ADVERSE DRUG REACTION (ADR) TO REGEN-COV (CASIRIVIMAB AND IMDEVIMAB)
por: Abou-Jaoude, E., et al.
Publicado: (2022)

Casirivimab/imdevimab: Lack of efficacy: case report
Publicado: (2022)

Use of Casirivimab and Imdevimab for the Treatment of COVID-19
por: Liu, Ryan, et al.
Publicado: (2022)

Efficacy of Casirivimab/Imdevimab in Kidney Transplant Recipients Admitted with Mild-to-Moderate COVID-19: A Case Series
por: Rajmane, Siddhavinayak Suryakant, et al.
Publicado: (2023)

Clinical Prognosis of Patients With Mild COVID-19 Treated With Casirivimab/Imdevimab in Japan
por: Osugi, Yasuhiro, et al.
Publicado: (2022)

Casirivimab-imdevimab neutralizing SARS-CoV-2: post-infusion clinical events and their risk factors
por: Yoshida, Junichi, et al.
Publicado: (2022)

Casirivimab - Imdevimab in Covid 19 – Early Indian experience
por: Venkitakrishnan, Rajesh, et al.
Publicado: (2022)

Casirivimab and Imdevimab for the Treatment of Hospitalized Patients With COVID-19
por: Somersan-Karakaya, Selin, et al.
Publicado: (2022)

Safety of casirivimab/imdevimab administration in a SARS-CoV-2 positive maintenance dialysis patient in Japan
por: Terakawa, Kanako, et al.
Publicado: (2022)

Effect of Casirivimab/Imdevimab Treatment on Serum Type I Interferon Levels in SARS-CoV-2 Infection
por: Nagaoka, Kentaro, et al.
Publicado: (2022)

Treatment of COVID-19 with monoclonal antibodies casirivimab and imdevimab in pregnancy
por: Folkman, Rebecca, et al.
Publicado: (2022)

Effectiveness of Subcutaneous Casirivimab and Imdevimab in Ambulatory Patients with COVID-19
por: Jalbert, Jessica J., et al.
Publicado: (2022)

Combination Therapy With Casirivimab/Imdevimab and Remdesivir for Protracted SARS-CoV-2 Infection in B-cell-Depleted Patients
por: Dioverti, M Veronica, et al.
Publicado: (2022)

Complications of rabbit anti-thymocyte globulin induction immunosuppression in HIV-infected kidney transplant recipients
por: Al Jurdi, Ayman, et al.
Publicado: (2022)

Ronapreve (REGN-CoV; casirivimab and imdevimab) reduces the viral burden and alters the pulmonary response to the SARS-CoV-2 Delta variant (B.1.617.2) in K18-hACE2 mice using an experimental design reflective of a treatment use case
por: Tatham, Lee, et al.
Publicado: (2023)

Characteristics and Outcomes of Recipients of Heart Transplant with Coronarvirus Disease 2019 Who Received Casirivimab Plus Imdevimab Infusion
por: Gaine, M., et al.
Publicado: (2022)

Effects of Casirivimab/Imdevimab Monoclonal Antibody Treatment among Vaccinated Patients Infected by SARS-CoV-2 Delta Variant
por: Cicchitto, Gaetano, et al.
Publicado: (2022)

Casirivimab/imdevimab lack of efficacy against COVID-19 Omicron variant
Publicado: (2022)

PROLONGED COVID-19 INFECTION IN AN IMMUNOSUPPRESSED PATIENT TREATED WITH CASIRIVIMAB/IMDEVIMAB
por: TOOR, SUBHAN A, et al.
Publicado: (2022)

Annular lichenoid eruption following treatment with casirivimab/imdevimab for COVID-19
por: Markovitz, Netana H., et al.
Publicado: (2022)

Breakthrough COVID-19 and casirivimab-imdevimab treatment during a SARS-CoV-2 B1.617.2 (Delta) surge
por: Bierle, Dennis M., et al.
Publicado: (2021)

Dégradation respiratoire post Casirivimab/Imdevimab : fréquence et facteurs de risque
por: Gerber, V., et al.
Publicado: (2022)

SARS-CoV-2 neutralizing antibody therapies: an early retrospective cohort study of 26 hospitalized patients treated with bamlanivimab or casirivimab/imdevimab
por: Heller, Martin, et al.
Publicado: (2023)

Emergent Inpatient Administration of Casirivimab and Imdevimab Antibody Cocktail for the Treatment of COVID-19 Pneumonia
por: Phan, Alexander T, et al.
Publicado: (2021)

506. Outpatient Bamlanivimab, Casirivimab and Imdevimab for COVID-19: Single Center Feasibility Analysis
por: Chundi, Vahini, et al.
Publicado: (2021)

1144. Rate of Infusion Reactions Among Patients Receiving Casirivimab/Imdevimab in the Home Setting
por: Simpson, Michelle, et al.
Publicado: (2022)

French pharmacovigilance survey of casirivimab - imdevimab monoclonal antibodies in coronavirus disease (COVID-19)
por: de Canecaude, Claire, et al.
Publicado: (2023)

Doubtful clinical benefit of casirivimab-imdevimab treatment for disease severity outcome of high-risk patients with SARS-CoV-2 delta variant infection
por: Shopen, Noah, et al.
Publicado: (2022)

Casirivimab–Imdevimab treatment is associated with reduced rates of hospitalization among high-risk patients with mild to moderate coronavirus disease-19
por: Razonable, Raymund R., et al.
Publicado: (2021)

Effects of casirivimab/imdevimab on systemic and mucosal immunity against SARS-CoV-2 in B-cell depleted patients with autoimmune rheumatic diseases refractory to vaccination
por: Fagni, Filippo, et al.
Publicado: (2022)

Vaccinated patients have reduced rates of hospitalization after receiving casirivimab and imdevimab for COVID-19
por: Zitek, Tony, et al.
Publicado: (2022)

Clinical efficacy of casirivimab-imdevimab antibody combination treatment in patients with COVID-19 Delta variant
por: Miyashita, Naoyuki, et al.
Publicado: (2022)

Repeat subcutaneous administration of casirivimab and imdevimab in adults is well-tolerated and prevents the occurrence of COVID-19
por: Isa, Flonza, et al.
Publicado: (2022)

Casirivimab/imdevimab + remdesivir in hospitalized patients with severe Covid-19: A single centre experience
por: Moriello, Nicola Schiano, et al.
Publicado: (2023)

Casirivimab and imdevimab: Cost-effectiveness analysis of the treatment based on monoclonal antibodies on outpatients with Covid-19
por: Ruggeri, Matteo, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_gt8vn8v8l7gp89alroqe5dgmkk